SC 13G

Names of reporting persons

H.I.G. BioVentures – Calhoun, LLC

Check the appropriate box if a member of a group (see instructions)

(a) ☐ (b) ☒

SEC use only

Citizenship or place of organization

Delaware

0001193125-22-041539.txt : 20220214 0001193125-22-041539.hdr.sgml : 20220214 20220214155302 ACCESSION NUMBER: 0001193125-22-041539 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20220214 DATE AS OF CHANGE: 20220214 GROUP MEMBERS: H.I.G. BIOVENTURES - CALHOUN, LLC GROUP MEMBERS: H.I.G.-GPII, INC. GROUP MEMBERS: SAMI MNAYMNEH SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: RxSight, Inc. CENTRAL INDEX KEY: 0001111485 STANDARD INDUSTRIAL CLASSIFICATION: OPHTHALMIC GOODS [3851] IRS NUMBER: 943268801 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-92778 FILM NUMBER: 22630912 BUSINESS ADDRESS: STREET 1: 100 COLUMBIA STREET STREET 2: SUITE 120 CITY: ALISO VIEJO STATE: CA ZIP: 92656 BUSINESS PHONE: 949-521-7822 MAIL ADDRESS: STREET 1: 100 COLUMBIA STREET STREET 2: SUITE 120 CITY: ALISO VIEJO STATE: CA ZIP: 92656 FORMER COMPANY: FORMER CONFORMED NAME: CALHOUN VISION INC DATE OF NAME CHANGE: 20000410 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: TAMER ANTHONY CENTRAL INDEX KEY: 0001050045 FILING VALUES: FORM TYPE: SC 13G MAIL ADDRESS: STREET 1: 1001 SOUTH BAYSHORE DRIVE STREET 2: STE 2708 CITY: MIAMI STATE: FL ZIP: 33131 SC 13G 1 d310943dsc13g.htm SC 13G SC 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. )*

RxSight, Inc.

(Name of Issuer)

Common Stock, $0.001 par value

(Title of Class of Securities)

78349D107

(CUSIP Number)

December 31, 2021

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(1)	Consists of 2,010,037 shares of Common Stock held of record by H.I.G. BioVentures – Calhoun, LLC.

(2)	Percentage ownership is calculated based on 27,366,746 shares of common stock of the Issuer outstanding as of December 31, 2021.

Page 2 of 9

(1)

Consists of 2,010,037 shares of Common Stock held of record by H.I.G. BioVentures – Calhoun, LLC. H.I.G.-GPII, Inc. is the Manager of H.I.G. BioVentures – Calhoun, LLC and has sole voting and investment control over the Shares owned by H.I.G. BioVentures – Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the sole shareholders of H.I.G.-GPII, Inc. and may be deemed to share beneficial ownership of the shares held by H.I.G. BioVentures – Calhoun, LLC.

(2)	Percentage ownership is calculated based on 27,366,746 shares of common stock of the Issuer outstanding as of December 31, 2021.

Page 3 of 9

(1)

(2)	Percentage ownership is calculated based on 27,366,746 shares of common stock of the Issuer outstanding as of December 31, 2021.

Page 4 of 9

(1)

(2)	Percentage ownership is calculated based on 27,366,746 shares of common stock of the Issuer outstanding as of December 31, 2021.

Page 5 of 9

Item 1(a)

Name of Issuer:

RxSight, Inc.

Item 1(b)

Address of Issuer’s Principal Executive Offices:

100 Columbia

Aliso Viejo, California 92656

Item 2

(a) Name of Person Filing:

This Schedule 13G is being filed by the following persons (each a “Reporting Person” and, collectively, the “Reporting Persons”):

H.I.G. BioVentures—Calhoun, LLC, a Delaware limited liability company;

ii.

H.I.G.-GPII, Inc., a Delaware Corporation (and, together with H.I.G. BioVentures – Calhoun, LLC, the “H.I.G. Entities”);

iii.

Anthony Tamer, a United States Citizen; and

iv.

Sami Mnaymneh, a United States Citizen

During the last five years, none of the Reporting Persons (i) has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) was a party to a civil proceeding of a judicial or other administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgement, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Item 2 (b)

Address of Principal Business Office or, if none, Residence:

The principal business address for each of the H.I.G. Entities, Mr. Tamer and Mr. Mnaymneh is 1450 Brickell Avenue, 31^st Floor, Miami, FL 33131

Item 2 (c)

Citizenship:

H.I.G. BioVentures – Calhoun, LLC is a Delaware limited liability company. H.I.G.-GPII, Inc. is a Delaware corporation. Mr. Tamer and Mr. Mnaymneh are U.S. Citizens.

Item 2 (d)

Title of Class of Securities:

Common stock, par value $0.001 per share

Item 2 (e)

CUSIP Number:

78349D107

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Page 6 of 9

Item 4.

Ownership.

(a)

Amount beneficially owned:

See Row 9 of cover page.

(b)

Percent of class:

See Row 11 of cover page.

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote:

See Row 5 of cover page for the Reporting Person.

(ii)

Shared power to vote or to direct the vote:

See Row 6 of cover page for the Reporting Person.

(iii)

Sole power to dispose or to direct the disposition of:

See Row 7 of cover page for the Reporting Person.

(iv)

Shared power to dispose or to direct the disposition of:

See Row 8 of cover page for the Reporting Person.

Item 5.

Ownership of 5 Percent or Less of a Class.

Not applicable.

Item 6.

Ownership of More than 5 Percent on Behalf of Another Person.

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group.

Not applicable.

Item 9.

Notice of Dissolution of Group.

Not applicable.

Item 10.

Certifications.

Not applicable.

Page 7 of 9

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2022

H.I.G. BioVentures – Calhoun, LLC

By: H.I.G.-GPII, Inc, its Manager

/s/ Richard Siegel

Title: Authorized Signatory

H.I.G.-GPII, Inc.

/s/ Richard Siegel

Title: Authorized Signatory

Anthony Tamer

/s/ Anthony Tamer

Sami Mnaymneh

/s/ Sami Mnaymneh

Page 8 of 9

EXHIBIT INDEX


Exhibit		Description

99.1		Joint Filing Agreement, dated as of February 14, 2022, by and among H.I.G. BioVentures – Calhoun, LLC, H.I.G.-GPII, Inc., Anthony Tamer, and Sami Mnaymneh

Page 9 of 9

EX-99.1 2 d310943dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

AGREEMENT OF JOINT FILING

This joint filing agreement (this “Agreement”) is made and entered into as of this 14th day of February 2022, by and among H.I.G. BioVentures – Calhoun, LLC, H.I.G.-GPII, Inc., Anthony Tamer, and Sami Mnaymneh. The parties to this Agreement hereby agree to prepare jointly and file timely (and otherwise to deliver as appropriate) all filings on any Schedule 13D or Schedule 13G, and any and all amendments thereto and any other document relating thereto (collectively, the “Filings”) required to be filed by them pursuant to the Securities Exchange Act of 1934, as amended. Each party to this Agreement further agrees and covenants to the other parties that it will fully cooperate with such other parties in the preparation and timely filing (and other delivery) of all such Filings.

This agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first set forth above.


H.I.G. BioVentures – Calhoun, LLC

By: H.I.G.-GPII, Inc.
Its: Manager

By:		/s/ Richard Siegel
Name:		Richard Siegel
Title:		Authorized Signatory

H.I.G.-GPII, Inc.

By:		/s/ Richard Siegel
Name:		Richard Siegel
Title:		Authorized Signatory

Anthony Tamer

/s/ Anthony Tamer

Sami Mnaymneh

/s/ Sami Mnaymneh